Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Trimmed by Perigon Wealth Management LLC

Perigon Wealth Management LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,566 shares of the biopharmaceutical company’s stock after selling 475 shares during the quarter. Perigon Wealth Management LLC’s holdings in Gilead Sciences were worth $3,443,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. nVerses Capital LLC bought a new position in Gilead Sciences in the 3rd quarter valued at about $25,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the second quarter worth approximately $33,000. Finally, Friedenthal Financial acquired a new stake in Gilead Sciences in the third quarter worth approximately $50,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock worth $42,130,461 in the last 90 days. 0.16% of the stock is owned by insiders.

Gilead Sciences Trading Down 1.6 %

Gilead Sciences stock opened at $93.85 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company’s fifty day simple moving average is $91.88 and its 200-day simple moving average is $85.27. The stock has a market cap of $116.96 billion, a P/E ratio of 1,042.78, a P/E/G ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GILD shares. Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Barclays boosted their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Finally, Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.